vs
Side-by-side financial comparison of STRATA Skin Sciences, Inc. (SSKN) and TECHPRECISION CORP (TPCS). Click either name above to swap in a different company.
STRATA Skin Sciences, Inc. is the larger business by last-quarter revenue ($9.3M vs $7.1M, roughly 1.3× TECHPRECISION CORP). STRATA Skin Sciences, Inc. runs the higher net margin — 0.6% vs -20.8%, a 21.4% gap on every dollar of revenue. On growth, STRATA Skin Sciences, Inc. posted the faster year-over-year revenue change (-3.0% vs -6.9%). STRATA Skin Sciences, Inc. produced more free cash flow last quarter ($-551.0K vs $-827.0K). Over the past eight quarters, STRATA Skin Sciences, Inc.'s revenue compounded faster (17.3% CAGR vs -9.2%).
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
TechPrecision Corp is a manufacturer of custom high-precision metal fabricated components and integrated systems, serving aerospace, defense, medical technology, renewable energy, and industrial end markets primarily across North America and Europe. It specializes in producing tight-tolerance, mission-critical parts that adhere to rigorous industry quality requirements.
SSKN vs TPCS — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $9.3M | $7.1M |
| Net Profit | $58.0K | $-1.5M |
| Gross Margin | 61.8% | 5.4% |
| Operating Margin | 5.3% | -19.1% |
| Net Margin | 0.6% | -20.8% |
| Revenue YoY | -3.0% | -6.9% |
| Net Profit YoY | 101.3% | -84.4% |
| EPS (diluted) | $0.14 | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.3M | $7.1M | ||
| Q3 25 | $6.9M | $9.1M | ||
| Q2 25 | $7.7M | $7.4M | ||
| Q1 25 | $6.8M | $9.5M | ||
| Q4 24 | $9.6M | $7.6M | ||
| Q3 24 | $8.8M | $8.9M | ||
| Q2 24 | $8.4M | $8.0M | ||
| Q1 24 | $6.8M | $8.6M |
| Q4 25 | $58.0K | $-1.5M | ||
| Q3 25 | $-1.6M | $825.0K | ||
| Q2 25 | $-2.6M | $-597.0K | ||
| Q1 25 | $-2.1M | $112.0K | ||
| Q4 24 | $-4.6M | $-799.0K | ||
| Q3 24 | $-2.1M | $-601.0K | ||
| Q2 24 | $-91.0K | $-1.5M | ||
| Q1 24 | $-3.4M | $-5.1M |
| Q4 25 | 61.8% | 5.4% | ||
| Q3 25 | 60.4% | 27.1% | ||
| Q2 25 | 56.2% | 14.0% | ||
| Q1 25 | 53.5% | 22.0% | ||
| Q4 24 | 61.4% | 13.0% | ||
| Q3 24 | 60.1% | 11.3% | ||
| Q2 24 | 59.0% | 3.0% | ||
| Q1 24 | 45.6% | 14.3% |
| Q4 25 | 5.3% | -19.1% | ||
| Q3 25 | -16.9% | 10.4% | ||
| Q2 25 | -30.1% | -6.3% | ||
| Q1 25 | -25.0% | 3.9% | ||
| Q4 24 | -44.7% | -9.1% | ||
| Q3 24 | -18.2% | -5.5% | ||
| Q2 24 | -5.7% | -16.8% | ||
| Q1 24 | -42.7% | -28.6% |
| Q4 25 | 0.6% | -20.8% | ||
| Q3 25 | -23.4% | 9.1% | ||
| Q2 25 | -33.6% | -8.1% | ||
| Q1 25 | -31.2% | 1.2% | ||
| Q4 24 | -47.6% | -10.5% | ||
| Q3 24 | -23.6% | -6.7% | ||
| Q2 24 | -1.1% | -18.3% | ||
| Q1 24 | -49.8% | -59.5% |
| Q4 25 | $0.14 | $-0.15 | ||
| Q3 25 | $-0.36 | $0.08 | ||
| Q2 25 | $-0.62 | $-0.06 | ||
| Q1 25 | $-0.51 | $0.01 | ||
| Q4 24 | $-2.01 | $-0.08 | ||
| Q3 24 | $-0.51 | $-0.06 | ||
| Q2 24 | $-0.03 | $-0.16 | ||
| Q1 24 | $-0.10 | $-0.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.9M | $50.0K |
| Total DebtLower is stronger | $15.3M | — |
| Stockholders' EquityBook value | $2.9M | $8.0M |
| Total Assets | $30.5M | $32.8M |
| Debt / EquityLower = less leverage | 5.28× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.9M | $50.0K | ||
| Q3 25 | $7.1M | $220.0K | ||
| Q2 25 | $6.0M | $143.0K | ||
| Q1 25 | $6.5M | $195.0K | ||
| Q4 24 | $7.3M | $165.0K | ||
| Q3 24 | $7.1M | $132.0K | ||
| Q2 24 | $5.5M | $44.8K | ||
| Q1 24 | $5.2M | $138.0K |
| Q4 25 | $15.3M | — | ||
| Q3 25 | $15.3M | — | ||
| Q2 25 | $15.0M | — | ||
| Q1 25 | $15.0M | $3.0K | ||
| Q4 24 | $15.0M | $19.0K | ||
| Q3 24 | $15.0M | — | ||
| Q2 24 | $15.0M | — | ||
| Q1 24 | $15.0M | — |
| Q4 25 | $2.9M | $8.0M | ||
| Q3 25 | $1.3M | $9.1M | ||
| Q2 25 | $532.0K | $8.2M | ||
| Q1 25 | $3.0M | $8.7M | ||
| Q4 24 | $5.0M | $8.1M | ||
| Q3 24 | $9.4M | $8.9M | ||
| Q2 24 | $9.5M | $7.9M | ||
| Q1 24 | $9.4M | $7.8M |
| Q4 25 | $30.5M | $32.8M | ||
| Q3 25 | $30.7M | $33.8M | ||
| Q2 25 | $29.5M | $32.1M | ||
| Q1 25 | $33.0M | $33.5M | ||
| Q4 24 | $34.9M | $32.2M | ||
| Q3 24 | $39.4M | $35.0M | ||
| Q2 24 | $38.8M | $35.7M | ||
| Q1 24 | $39.2M | $34.7M |
| Q4 25 | 5.28× | — | ||
| Q3 25 | 11.65× | — | ||
| Q2 25 | 28.20× | — | ||
| Q1 25 | 5.04× | 0.00× | ||
| Q4 24 | 3.02× | 0.00× | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.58× | — | ||
| Q1 24 | 1.59× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-239.0K | $183.0K |
| Free Cash FlowOCF − Capex | $-551.0K | $-827.0K |
| FCF MarginFCF / Revenue | -5.9% | -11.7% |
| Capex IntensityCapex / Revenue | 3.4% | 14.2% |
| Cash ConversionOCF / Net Profit | -4.12× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-4.4M | $-4.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-239.0K | $183.0K | ||
| Q3 25 | $-64.0K | $-1.1M | ||
| Q2 25 | $-1.9M | $646.0K | ||
| Q1 25 | $-550.0K | $396.0K | ||
| Q4 24 | $703.0K | $-570.0K | ||
| Q3 24 | $-302.0K | $-532.0K | ||
| Q2 24 | $591.0K | $107.0K | ||
| Q1 24 | $-804.0K | $-452.0K |
| Q4 25 | $-551.0K | $-827.0K | ||
| Q3 25 | $-1.1M | $-2.1M | ||
| Q2 25 | $-2.0M | $-604.0K | ||
| Q1 25 | $-749.0K | $-930.0K | ||
| Q4 24 | $199.0K | $-1.7M | ||
| Q3 24 | $-364.0K | $-2.0M | ||
| Q2 24 | $246.0K | $-94.0K | ||
| Q1 24 | $-1.5M | $-900.0K |
| Q4 25 | -5.9% | -11.7% | ||
| Q3 25 | -15.6% | -22.9% | ||
| Q2 25 | -26.1% | -8.2% | ||
| Q1 25 | -11.0% | -9.8% | ||
| Q4 24 | 2.1% | -22.9% | ||
| Q3 24 | -4.1% | -21.8% | ||
| Q2 24 | 2.9% | -1.2% | ||
| Q1 24 | -22.6% | -10.5% |
| Q4 25 | 3.4% | 14.2% | ||
| Q3 25 | 14.7% | 11.0% | ||
| Q2 25 | 0.8% | 16.9% | ||
| Q1 25 | 2.9% | 14.0% | ||
| Q4 24 | 5.3% | 15.4% | ||
| Q3 24 | 0.7% | 15.9% | ||
| Q2 24 | 4.1% | 2.5% | ||
| Q1 24 | 10.7% | 5.2% |
| Q4 25 | -4.12× | — | ||
| Q3 25 | — | -1.31× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 3.54× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
TPCS
| Defense | $6.7M | 94% |
| Other | $410.0K | 6% |
